Home Monitoring Saves Lives and Costs

IN-TIME Trial Confirms a 50 Percent Reduction in Mortality in Heart Failure Patients while EuroEco and ECOST Demonstrate Economic Savings

BARCELONA, September 2, 2014 – Experts discussed the benefits of Home Monitoring technology from the perspective of patients, hospitals and payers for the first time at a press conference held by BIOTRONIK at the European Society of Cardiology’s annual congress, ESC Congress 2014. Dr. Gerhard Hindricks, University of Leipzig Heart Center, Germany; Dr. Ignacio Fernandez Lozano, University Hospital Puerta de Hierro, Madrid, Spain; and Dr. Christophe Leclercq, Rennes University Hospital, France, all agree that Home Monitoring clearly improves patient health. This has been confirmed by comprehensive clinical trials involving more than 24,000 patients.

“After the European Society of Cardiology added a clear recommendation for the use of implant-based remote follow-up to its guidelines last year,1 now is the time for payers – health insurers and national health care systems – to acknowledge remote monitoring’s value for patients by reimbursing physicians follow-up and the technology itself,” explained Dr. Hindricks.

The IN-TIME trial, which was recently published in The Lancet, demonstrated that heart failure patients’ mortality can be reduced by more than 50 percent using BIOTRONIK Home Monitoring®.2 “These are excellent results that we would not have been able to obtain in the patient group by using drug therapy alone or another remote monitoring technology,” commented lead investigator Dr. Hindricks. “We are making critical advances in patient therapy with implant-based telemedicine. BIOTRONIK Home Monitoring quickly detects clinically relevant events, so we can adjust the therapy at the right time. This is crucial, especially when managing patients with heart failure whose condition changes quickly and often.”

The experts from the three countries confirmed that Home Monitoring is integral to their daily practice and they emphasized that remote follow-up does not create a higher workload since patients only come to the hospital when there is a medical need, rather than on a rigid calendar schedule. “At my hospital, we use Home Monitoring for all implantable defibrillator – ICD and CRT-D – patients. This allows us to detect events as they occur so I can spend time on patients that need my attention most,” emphasized Dr. Lozano.

“Patients' wellbeing is our top priority,” added Dr. Leclercq. “Remote monitoring is a treatment option that clearly improves patient health without incurring additional costs for hospitals or payers. It should be adopted, and physician follow-up and the Home Monitoring technology should be adequately reimbursed.”

Based on the French health care system, the ECOST3 trial demonstrated a cost reduction of over 300 euros per patient per year. Reimbursement for medical services performed during remote follow-up is now being discussed in France for the first time.

Remote follow-up is already reimbursed in Germany and the United Kingdom. Even in these countries, the EuroEco trial found no increase in costs for insurance providers or national health care systems. EuroEco, presented at ESC Congress 2014, identified a trend towards cost savings for payers with the use of Home Monitoring.4 This was caused by fewer hospital admissions and shorter lengths of stays, reinforcing previous findings about reductions in hospitalizations and strokes from trials including TRUST5, COMPAS6 and ECOST7.

  1. Brignole M et al. 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. European Heart Journal. 2013, 34(29).
  2. Hindricks G et al. The Lancet. 2014, 384(9943).
  3. Guedon-Moreau L et al. Europace. 2014, 16(8).
  4. Heidbuchel H. Presentation at ESC Congress 2014.
  5. Varma V et al. Circulation. 2010, 122(4).
  6. Mabo P et al. European Heart Journal. 2012, 33.
  7. Guedon-Moreau L et al. European Heart Journal. 2013, 34(8).


At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.